Da Vià, Matteo C.
Dietrich, Oliver http://orcid.org/0000-0002-4776-8960
Truger, Marietta
Arampatzi, Panagiota http://orcid.org/0000-0001-7925-8984
Duell, Johannes
Heidemeier, Anke
Zhou, Xiang
Danhof, Sophia http://orcid.org/0000-0003-1316-0241
Kraus, Sabrina
Chatterjee, Manik
Meggendorfer, Manja
Twardziok, Sven
Goebeler, Maria-Elisabeth
Topp, Max S.
Hudecek, Michael http://orcid.org/0000-0002-2280-2202
Prommersberger, Sabrina http://orcid.org/0000-0003-4276-2268
Hege, Kristen
Kaiser, Shari
Fuhr, Viktoria
Weinhold, Niels
Rosenwald, Andreas
Erhard, Florian http://orcid.org/0000-0002-3574-6983
Haferlach, Claudia
Einsele, Hermann http://orcid.org/0000-0002-7680-0819
Kortüm, K. Martin http://orcid.org/0000-0002-7011-0286
Saliba, Antoine-Emmanuel http://orcid.org/0000-0001-8539-2784
Rasche, Leo http://orcid.org/0000-0002-9536-9649
Funding for this research was provided by:
Deutsche Krebshilfe (MSNZ programm)
Interdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum Würzburg (Z-3R/2)
Deutsche Forschungsgemeinschaft (GRK2157, 2157)
Article History
Received: 12 August 2020
Accepted: 12 January 2021
First Online: 22 February 2021
Competing interests
: K.H. and S.K. are employees of Bristol Myers Squibb. M.H. is listed as an inventor on patent applications and granted patents related to CAR T cell therapy and CAR T cell technologies; he has received speaker honoraria from Celgene/Bristol Myers Squibb, Janssen and Kite/Gilead. H.E. received research funding from Janssen, Bristol Myers Squibb/Celgene, Amgen, Novartis, Sanofi, GSK and Janssen and has received speaker honoraria from Bristol Myers Squibb/Celgene, Amgen, Novartis, Takeda, Sanofi and GSK. L.R. has received speaker honoraria from Bristol Myers Squibb/Celgene, Sanofi, GSK, Oncopeptides and Janssen. The remaining authors declare no competing interests.